Advancing China’s end tuberculosis strategy goals leveraged by active case finding and preventive therapy

Мұқаба

Дәйексөз келтіру

Толық мәтін

Аннотация

Tuberculosis remains a major public health issue in China, with 741,000 new cases in 2023. Despite significant strides in tuberculosis control, suboptimal case detection and low acceptance rate of tuberculosis preventive treatment hamper tuberculosis elimination. To meet the WHO’s 2030 End Tuberculosis target, China’s “National Tuberculosis Prevention and Control Program (2024–2030)” prioritizes active case finding and preventive treatment. Active case finding targets high-risk groups (people living with human immunodeficiency virus/acquired immunodeficiency syndrome, the elderly, individuals with diabetes and previously treated tuberculosis patients and close contacts of tuberculosis patients) using advanced screening methods. Implementation of active case finding should be performed in setting- ang region-specific manner. Tuberculosis preventive treatment focuses on latent tuberculosis infections with shorter, safer regimens. The effective implementation of tuberculosis preventive treatment requires integration into the comprehensive “Center for Disease Control and Prevention − Hospital − Primary Medical Institutions” framework. The “Zero-TB Communities” initiative integrates these strategies, aiming at fewer than 10 cases per 100,000 people. The framework of this initiative includes screening for active tuberculosis cases, drug resistant tuberculosis and latent tuberculosis infection, management of identified tuberculosis cases and tuberculosis preventive treatment, as long as social advocacy and mobilization. Through evidence-based interventions and multi-sector collaboration, China aims to accelerate tuberculosis control and contribute to global elimination efforts.

Авторлар туралы

Caihong Xu

Email: zhaoyl@chinacdc.cn

Yanlin Zhao

Хат алмасуға жауапты Автор.
Email: zhaoyl@chinacdc.cn

Әдебиет тізімі

  1. Xu C, Zhao Y. Commit, invest and deliver: towards achieving end tuberculosis strategy goals through active case finding and preventive treatment in China. China CDC Wkly. 2025;7(13):407-412.
  2. https://doi.org/10.46234/ccdcw2025.068
  3. Li T, Du X, Kang J, et al. Patient, diagnosis, and treatment delays among tuberculosis patients before and during COVID-19 epidemic - China, 2018-2022. China CDC Wkly. 2023;5(12):259-265.
  4. https://doi.org/10.46234/ccdcw2023.047
  5. Frascella B, Richards AS, Sossen B, et al. Subclinical tuberculosis disease - a review and analysis of prevalence surveys to inform definitions, burden, associations, and screening methodology. Clin Infect Dis. 2021;73(3):e830-e841. https://doi.org/10.1093/cid/ciaa1402
  6. Fox GJ, Nhung NV, Sy DN, et al. Household-contact investigation for detection of tuberculosis in Vietnam. N Engl J Med. 2018;378(3):221-229.
  7. https://doi.org/10.1056/NEJMoa1700209
  8. Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in postmortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015;29(15):1987-2002. https://doi.org/10.1097/QAD.0000000000000802
  9. Liu Q, Chen Q, Guo Y, et al. Feasibility of eliminating tuberculosis by shortening the diagnostic delay: A retrospective analysis and modelling study in China during the pre-COVID-19 era. Heliyon. 2024;10(15):e35016.
  10. https://doi.org/10.1016/j.heliyon.2024.e35016
  11. ↑7. Donald PR, Marais BJ, Barry CE 3rd. Age and the epidemiology and pathogenesis of tuberculosis. Lancet. 2010;375(9729):1852-1854.
  12. https://doi.org/10.1016/S0140-6736(10)60580-6
  13. ↑8. Pratt RH, Winston CA, Kammerer JS, Armstrong LR. Tuberculosis in older adults in the United States, 1993-2008. J Am Geriatr Soc. 2011;59(5):851-857.
  14. https://doi.org/10.1111/j.1532-5415.2011.03369.x
  15. Baussano I, Williams BG, Nunn P, et al. Tuberculosis incidence in prisons: a systematic review. PLoS Med. 2010;7(12):e1000381. https://doi.org/10.1371/journal.pmed.1000381
  16. Barboza CEG, Winter DH, Seiscento M, et al. Tuberculosis and silicosis: epidemiology, diagnosis and chemoprophylaxis. J bras pneumol. 2008;34(11):959- 966. (In Portuguese).
  17. https://doi.org/10.1590/S1806-37132008001100012
  18. Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161(4 Pt 2):S221-S247. https://doi.org/10.1164/ajrccm.161.supplement_3.ats600
  19. Xu C, Zhang W, Zhao Y, Conduct Community- and Facility-Based Active Screening to Enhance Tuberculosis Cases Detection. Chin J Infect Dis. 2025, 43(03):129-134. (In Chinese).
  20. https://doi.org/10.3760/cma.j.cn311365-20250303-00067
  21. Zu XW, Yao YX, Gong DH. Acceptability of 6-month prophylactic isoniazid therapy in latently infected close contacts of tuberculosis patients. Chin J Public Health. 2020;36(3):369-374. (In Chinese).
  22. https://doi.org/10.11847/zgggws1127769
  23. Yao X, Wu CG, Gong DH, et al. Analysis of treatment completeness and its influencing factors of 12-week preventive therapy among close contacts of pulmonary tuberculosis patients. CJATB. 2021;43(3):233-239. (In Chinese).
  24. https://doi.org/10.3969/j.issn.1000-6621.2021.03.008
  25. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11-20.
  26. https://doi.org/10.1056/NEJMoa1005136
  27. Caruso E, Mangan JM, Maiuri A, Bouwkamp B, DeLuca N. Tuberculosis testing and latent tuberculosis infection treatment practices among health care providers - United States, 2020-2022. MMWR Morb Mortal Wkly Rep. 2023;72(44):1183-1189. https://doi.org/10.15585/mmwr.mm7244a2
  28. Wang YT, Chee CB, Hsu LY, et al. Ministry of Health clinical practice guidelines: prevention, diagnosis and management of . tuberculosis. Singapore Med J. 2016;57(3):118-125.
  29. https://doi.org/10.11622/smedj.2016051

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML